Antonio Antón

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis

Sebastián Morán, Anna Martínez‐Cardús, Sergi Sayols et al. · The Lancet Oncology · 2016 · 497 citations

Oncology, Tumor Heterogeneity, Unknown Primary +13

Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer

Felipe Cardenal, M.P. López-Cabrerizo, Antonio Antón et al. · Journal of Clinical Oncology · 1999 · 476 citations

Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer

Ricardo Hitt, Antonio López–Pousa, Javier Martínez‐Trufero et al. · Journal of Clinical Oncology · 2005 · 451 citations

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

José Trigo, Vivek Subbiah, Benjamin Besse et al. · The Lancet Oncology · 2020 · 433 citations

Second-line Treatment, Oncology, Metronomic Therapy +9

PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers

Roy R. L. Bastien, Álvaro Rodríguez-Lescure, Mark Ebbert et al. · BMC Medical Genomics · 2012 · 336 citations · Full text